Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial
Summary
CONCLUSIONS Initial treatment with camrelizumab plus CAPOX followed by camrelizumab based maintenance was associated with longer overall survival than CAPOX alone in human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Exploratory comparisons between the two camrelizumab based regimens showed no additional survival benefit, with higher rates of treatment related adverse events of grade
Content
# Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial
*Published: 2026 Mar 12*
## CONCLUSIONS
Initial treatment with camrelizumab plus CAPOX followed by
camrelizumab based maintenance was associated with longer overall survival than
CAPOX alone in human epidermal growth factor receptor 2 (HER2) negative,
unresectable, locally advanced or metastatic gastric or gastro-oesophageal
junction adenocarcinoma. Exploratory comparisons between the two camrelizumab
based regimens showed no additional survival benefit, with higher rates of
treatment related adverse events of grade ≥3 and treatment discontinuations when
apatinib was added during maintenance.
## TRIAL REGISTRATION
ClinicalTrials.gov NCT03813784.
DOI: 10.1136/bmj-2025-086115